New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes
Open Access
- 7 August 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 35 (40), 2797-2815
- https://doi.org/10.1093/eurheartj/ehu204
Abstract
The management of heart failure with reduced ejection fraction (HF-REF) has improved significantly over the last two decades. In contrast, little or no progress has been made in identifying evidence-based, effective treatments for heart failure with preserved ejection fraction (HF-PEF). Despite the high prevalence, mortality, and cost of HF-PEF, large phase III international clinical trials investigating interventions to improve outcomes in HF-PEF have yielded disappointing results. Therefore, treatment of HF-PEF remains largely empiric, and almost no acknowledged standards exist. There is no single explanation for the negative results of past HF-PEF trials. Potential contributors include an incomplete understanding of HF-PEF pathophysiology, the heterogeneity of the patient population, inadequate diagnostic criteria, recruitment of patients without true heart failure or at early stages of the syndrome, poor matching of therapeutic mechanisms and primary pathophysiological processes, suboptimal study designs, or inadequate statistical power. Many novel agents are in various stages of research and development for potential use in patients with HF-PEF. To maximize the likelihood of identifying effective therapeutics for HF-PEF, lessons learned from the past decade of research should be applied to the design, conduct, and interpretation of future trials. This paper represents a synthesis of a workshop held in Bergamo, Italy, and it examines new and emerging therapies in the context of specific, targeted HF-PEF phenotypes where positive clinical benefit may be detected in clinical trials. Specific considerations related to patient and endpoint selection for future clinical trials design are also discussed.Keywords
This publication has 147 references indexed in Scilit:
- The Impact of Extra Cardiac Comorbidities on Pressure Volume Relations in Heart Failure and Preserved Ejection FractionJournal of Cardiac Failure, 2011
- Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatmentEuropean Heart Journal, 2010
- Association of glucose metabolism with diastolic function along the diabetic continuumDiabetologia, 2010
- Vitamin B1 Analog Benfotiamine Prevents Diabetes-Induced Diastolic Dysfunction and Heart Failure Through Akt/Pim-1–Mediated Survival PathwayCirculation: Heart Failure, 2010
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Longitudinal Tracking of Left Ventricular Mass Over the Adult Life CourseCirculation, 2009
- Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Community-Based StudyJournal of the American College of Cardiology, 2009
- Rationale and design of the Karolinska‐Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fractionEuropean Journal of Heart Failure, 2009
- Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programmeHeart, 2007
- Effects of Digoxin on Morbidity and Mortality in Diastolic Heart FailureCirculation, 2006